Pharmaceutical Composition with Palmitoyl Chitosan for Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions lack long-term release and injectability characteristics, making it difficult to effectively deliver bioactive substances to specific tissue areas in biomedical applications.
Innovation Solution
A pharmaceutical composition incorporating hydrophobically modified chitosan with palmitoyl groups and a gelling accelerating agent, which forms a pH-responsive hydrogel system for sustained release of active agents, enhancing biocompatibility and extended release time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional pharmaceutical compositions are used, then injectability is achieved, but long-term release characteristic is lacking
Solution Approach 1:
The patent employs composite materials by combining chitosan with palmitoyl groups (a hydrophobically modified polysaccharide) to create a hydrogel system that provides both injectability and long-term release characteristics. The composite structure allows the material to maintain fluid properties for injection while forming a sustained-release matrix after implantation.
Solution Approach 2:
The patent utilizes parameter changes by modifying chitosan through hydrophobic modification with palmitoyl groups, which alters the physical and chemical properties of the base material. This modification enables the chitosan to form pH-responsive hydrogels that can be injected as fluids but gel in situ to provide extended drug release.
2Duration of action of moving object
If pH-responsive hydrogel system is formed, then long-term release is achieved, but biocompatibility must be enhanced
Solution Approach 1:
The patent uses parameter changes by exploiting the pH-responsive properties of the hydrogel system. The hydrogel undergoes sol-gel transition based on pH changes in the body environment, allowing it to be injected as a fluid at one pH and gel at physiological pH, thereby achieving both long-term release and biocompatibility.
Solution Approach 2:
The hydrogel system exhibits self-service characteristics by automatically responding to pH changes in the body environment. The material self-regulates its physical state (fluid to gel transition) based on the local pH conditions, eliminating the need for external control mechanisms and enhancing biocompatibility.
3Duration of action of moving object
If chitosan with palmitoyl groups is used, then sustained release is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of chitosan through hydrophobic modification with palmitoyl groups. This chemical modification changes the solubility and gelation properties of chitosan, enabling sustained release while maintaining a relatively straightforward manufacturing process involving standard chemical modification techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves long-term release of active agents, maintaining therapeutic effects for over 60 days, with enhanced biocompatibility and efficient drug delivery, suitable for various biomedical applications including cancer and hormone deficiency treatments.
Implementation Method 1
hydrophobically modified chitosan with palmitoyl groups
Implementation Method 2
forms a pH-responsive hydrogel system
Implementation Method 3
the drugs are released over time, achieving therapeutic effects
Data Source
AI summary
The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.